FindMyKOL
Clinical trialNCT04878952TerminatedInterventional

Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer

NCT04878952 is an interventional trial sponsored by NRG Oncology. As of 21 Nov 2026, it was terminated. It studies Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III and 1 more condition. The registry lists an enrollment of 3 participants at 5 sites in 1 country. The registry lists a start date of 26 Aug 2021 and a primary completion date of 12 Aug 2024. One of its registered investigators has a FindMyKOL profile.

SponsorNRG Oncology →Enrollment3Non-small Cell Lung CancerNon-small Cell Lung Cancer Stage IIIRecurrent Non Small Cell Lung Cancer
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04878952
FieldValue
Registry IDNCT04878952
StatusTerminated
Study typeInterventional trial
Lead sponsorNRG Oncology
Enrollment3
Registered sites5
Countries1
ConditionsNon-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III and Recurrent Non Small Cell Lung Cancer
Start26 Aug 2021
Primary completion12 Aug 2024
Study completion12 Aug 2024
Last update posted8 May 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This trial will examine if the monitoring of daily step counts during a course of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer will enable clinicians to deliver improved supportive care and reduce the rate of adverse events during the course of radiation treatment.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Pennsylvania, United States5 sites
  • Wellspan Health - Chambersburg

    Chambersburg

  • Wellspan Health - Ephrata

    Ephrata

  • Wellspan Health - Gettysburg

    Gettysburg

  • Wellspan Health - Lebanon

    Lebanon

  • Wellspan Health - York

    York

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvania: 5 sitesPA5New JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT04878952

Each answer restates registry values shown on this page.

What is NCT04878952?

NCT04878952 is an interventional trial sponsored by NRG Oncology. It studies Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III and 1 more condition.

Who leads NCT04878952?

The registry names Nitin Ohri, MD (principal investigator, NRG Oncology) as the overall official.

Where does NCT04878952 run?

The registry lists 5 sites in 1 country. Every site with a stated country is in one country: United States.

When did NCT04878952 end?

The registry lists a primary completion date of 12 Aug 2024 and a study completion date of 12 Aug 2024. The sponsor last updated the record on 8 May 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.